Search

Your search keyword '"Wendy Osborne"' showing total 80 results

Search Constraints

Start Over You searched for: Author "Wendy Osborne" Remove constraint Author: "Wendy Osborne"
80 results on '"Wendy Osborne"'

Search Results

1. Home-based EXercise and motivAtional programme before and after Liver Transplantation (EXALT): study protocol for phase II two-centre, randomised controlled trial

2. Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes

3. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

4. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

5. P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

6. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY)

7. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

8. Prevalence of leakage and its negative impact on quality of life in people living with a stoma in the UK

9. CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam

10. A national service for delivering <scp>CD19 CAR‐T</scp> in large B‐cell lymphoma – The <scp>UK</scp> real‐world experience

11. Gaining consensus: the challenges of living with a stoma and the impact of stoma leakage

12. Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma

13. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma

16. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

17. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort

18. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

19. American Society of Hematology 2020 Podcast Collection: FL and DLBCL

21. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

22. Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline

24. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

25. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

26. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

27. MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA

28. THE PATIENT AND CARER EXPERIENCE OF CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY FOR RELAPSED/REFRACTORY B‐CELL LYMPHOMA AT A UK REGIONAL CENTRE

29. OUTCOME OF LARGE B‐CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR‐T THERAPY

30. REAL WORLD OUTCOMES AND RESPONSES TO SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTRE UK STUDY

31. EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR‐T

32. 9P GAIN PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX +/‐ ATEZOLIZUMAB. ARGO: A RANDOMISED PHASE II STUDY

33. POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB FOR RELAPSED/REFRACTORY HIGH‐GRADE B‐CELL LYMPHOMA: THE UK EXPERIENCE

34. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

35. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients

36. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

37. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

38. DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B‐cell lymphoma

39. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia

40. ASCN UK Guideline: parastomal hernias

41. Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

42. Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

43. Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

44. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

45. Advanced practice is key

46. 890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

47. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

48. Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

49. Using a risk assessment tool for parastomal hernia prevention

50. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY

Catalog

Books, media, physical & digital resources